| Bioactivity | Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonal antibody that binds CD56 (NCAM1). Lorvotuzumab can be used to synthesize an ADC compound, Lorvotuzumab mertansine[1]. |
| Invitro | Lorvotuzumab mertansine (IMGN901) 是一种 ADC，可通过二硫键连接强效抗有丝分裂 (DM1) 与 CD56 靶向抗体 (Lorvotuzumab)。 Lorvotuzumab mertansine 抗肾母细胞瘤、横纹肌肉瘤和神经母细胞瘤。 |
| Name | Lorvotuzumab |
| CAS | 339306-30-8 |
| Appearance | Liquid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. James I Geller, et al. ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study. Cancer. 2020 Dec 15;126(24):5303-5310. |